CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain on January 20, 2027. There are 2 upcoming events on record.
| Date | Event | Type | Phase |
|---|---|---|---|
| January 20, 2027 | Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain | Trial Milestone | Phase 1/Phase 2 |
| January 31, 2027 | Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes | Trial Milestone | Phase 1/Phase 2 |
Track CELZ alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open CELZ in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| September 25, 2026 | 8-K filed: Material agreement | Corporate | — |
| July 2, 2026 | 8-K filed: Material agreement, Leadership change | Corporate | — |
| November 12, 2025 | 8-K filed: Leadership change | Corporate | — |
| October 31, 2025 | 8-K filed: Material agreement | Corporate | — |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.